Dr. Vande Casteele is Vice President, Early Clinical Development & Pharmacology at Mirador Therapeutics, San Diego, California where he is responsible for the strategy, leadership, and implementation of clinical development aspects across programs from preclinical through Phase 2 proof-of-concept. His responsibilities include providing strategic drug development input, clinical leadership to cross-functional teams, and enabling operational excellence of development programs across the portfolio. In addition to his functional role, he serves as the Project Team Lead for Mirador’s lead asset.
Dr. Vande Casteele has over a decade of experience in public-private research in the field of drug discovery and development for chronic immune-mediated diseases. He excels in leading strategic, scientific and medical aspects of clinical research and multicenter global clinical trials with focus on integration of clinical pharmacology and translational medicine principles to enable efficient early drug development.
Dr. Vande Casteele holds a Bachelor in Pharmaceutical Sciences and a Master in Drug Design and Development, he is a Doctor of Pharmacy (Pharm.D.), and he obtained his Ph.D. in Pharmaceutical Sciences focused on Precision Medicine from KU Leuven, Belgium. He has published over 140 peer reviewed research articles and book chapters, gave over 40 invited lectures globally, and received awards for his research contributions from distinguished professional organizations in the United States and Europe. He continues to hold a faculty appointment as Associate Adjunct Professor of Medicine at UC San Diego, California, where he teaches a course on Biologics and Biosimilars Drug Development and mentors the next generation of pharmaceutical professionals.